Kyverna Therapeutics, Inc. KYTX Accrued Compensation
Accrued Compensation at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedEmployeeBenefitsCurrent.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s accrued compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s accrued compensation?
- Kyverna Therapeutics, Inc. (KYTX) reported accrued compensation of $3.11M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s accrued compensation changed year-over-year?
- Kyverna Therapeutics, Inc.'s accrued compensation increased by 1.1% year-over-year, from $3.08M to $3.11M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s accrued compensation?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s accrued compensation has grown at a 88.5% compound annual growth rate (CAGR), from $2.81M to $9.99M.
- What does accrued compensation mean?
- Employee wages, salaries, bonuses, commissions, and benefits earned but not yet paid as of the reporting date.